New data show sharp growth in pharmacists’ clinical roles, from the intensive care unit to outpatient chronic disease ...

The hazard of the progression of intermediate age-related macular degeneration (iAMD) was higher in those whose complement ...

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

On-body delivery systems for subcutaneous isatuximab could enable patient self-administration, according to Xavier Leleu, MD, PhD, improving convenience and transforming treatment for ...

Panelists discuss recent phase 3 trial results of a novel oral agent for idiopathic pulmonary fibrosis (IPF) and progressive ...

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

Panelists discuss exciting phase 3 trial data on a novel selective phosphodiesterase inhibitor that elevates intracellular ...

Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how ...

Controversy surrounds the Advisory Committee on Immunization Practices’ (ACIP) first meeting under new leadership as vaccine skeptics join the panel.

The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...

Patients with relapsed/refractory myeloma from lower socioeconomic groups face worse quality of life, even in countries with universal health care, according to Francesco Sparano, MSc, of the ...

Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the ...